---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-010456"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T07:06:48.872714+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# bioAffinity reports FY2022 net loss $8.2M ($1.81/sh), revenue $5K; cash $11.4M, plans pivotal trial 2023

## Summary
- FY2022 net loss $8.2M ($1.81/sh) vs $6.3M ($2.36/sh) in 2021; revenue $5K from CyPath Lung LDT.
- Q4 2022 net loss $1.7M, revenue $2,500; cash and equivalents $11.4M as of Dec 31, 2022.
- Raised net $6.0M from IPO in Sep 2022; additional $7.8M from warrant/option exercises.
- CyPath Lung clinical validation: 92% sensitivity, 87% specificity in high-risk patients; AUC 94%.
- Pivotal trial for FDA clearance to recruit 1,800 patients starting in 2023.

## SEC filing metadata
- accession: 0001493152-23-010456
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315223010456/0001493152-23-010456-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315223010456/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-010456
- JSON: https://secwatch.observer/filing/0001493152-23-010456.json
- Plain text: https://secwatch.observer/filing/0001493152-23-010456.txt

## Key facts
- Earnings Releases
  bioAffinity Technologies, Inc. reported the three and 12 months ended December 31, 2022 results: revenue approximately $2,500, net income Net loss for the fourth quarter of 2022 was $1.7 million.
  - Period: the three and 12 months ended December 31, 2022
  - Revenue: approximately $2,500
  - Net income: Net loss for the fourth quarter of 2022 was $1.7 million
  - Result: reported results
  source text: Revenue for the fourth quarter of 2022 was approximately $2,500, compared with no revenue for the prior-year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1712762/000149315223010456/0001493152-23-010456-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.